Skye Bioscience gets Nasdaq notice after negative $497,307 stockholders' equity
Nasdaq notified Skye Bioscience on August 18, 2026 that its stockholders' equity of ($497,307), as reported in its June 30, 2026 quarterly report, falls short of the $2,500,000 minimum under Nasdaq Capital Market Listing Rule 5550(b)(1). The notice has no immediate effect on the listing, and the stock continues to trade as SKYE, but the company must submit a plan to regain compliance and says there is no assurance it will do so. The notice comes alongside a pending acquisition of Redx Pharma Limited, which adds uncertainty for shareholders.
Key points
- Stockholders' equity was ($497,307) versus a $2,500,000 minimum under Nasdaq Listing Rule 5550(b)(1)
- Stock continues to trade on the Nasdaq Capital Market under SKYE; the notice has no immediate effect on listing
- Compliance plan due October 2, 2026; if accepted, Nasdaq can grant an extension to February 14, 2027
- Company is evaluating alternatives and says there can be no assurance it will regain compliance; Redx transaction agreement is dated August 14, 2026
The filing
Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 18, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.